GlobeNewswire All Public CompaniesQwen · 实盘不做把握 0/10不做原因:不是事件🔁 +1 同一事件
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:00:40·⚡ 决策 08-31 20:34:05 +1h33m·57.2 天前
Beam Therapeutics宣布管理层将参加2026年9月三场投资者会议
这是标准的投资者会议参加公告，仅列出管理层将在三场行业会议上进行炉边对话的时间地点，不含任何新临床数据、监管里程碑、财务指引、合作协议或管线进展。此类公告不改变市场对公司基本面的任何预期，无法形成交易方向或正期望边际。
📄 原文GlobeNewswire All Public Companies↗ 原文
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company deve…
不做 Beam Therapeutics（BEAM.US）
例行投资者会议参加公告，不含任何新增临床数据、监管进展、财务指引或业务合作信息，无法构成交易催化，无方向、无edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Beam Therapeutics通过GlobeNewswire发布例行公告，宣布管理层将参加2026年9月8-10日的三场投资者会议（Wells Fargo/Citi/Cantor Fitzgerald）。公告全文无新增临床、监管、财务或业务事实，属于最基础的IR日程披露。投资者会议参加本身不改变任何基本面预期，历史上此类公告对股价无统计显著影响。结论：无催化、无方向、无edge，不做。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例研究，事件本身不含任何催化信息
方向:不适用——例行会议参加公告不构成事件，无需先例校准
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 9,167 ms
{"result": "search_processed_events:agent query=`beam fireside chat september 2026 | beam therapeutics investor conference participation | beam therapeutics wells fargo citi cantor conference`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.3/72 小时、1070 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；
原文全文
展开原文 · 1,742 字
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) --
Beam Therapeutics Inc.
(Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Wells Fargo 21
st
Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York
The live webcasts will be available in the investor section of the company's website at
www.beamtx.com
and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Beam Therapeutics Inc.
(Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Wells Fargo 21
st
Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York
The live webcasts will be available in the investor section of the company's website at
www.beamtx.com
and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。